Professor Paul Moss

Professor Paul Moss

Institute of Immunology and Immunotherapy
Deputy Head of College of Medical and Dental Sciences
Professor of Haematology

Contact details

Institute of Immunology and Immunotherapy
University of Birmingham
Cancer Sciences Building
B15 2TT
What is the UK Coronavirus Immunology Consortium?
What does COVID-19 look like and how do the vaccines work?

Professor Moss is Professor of Haematology within the Institute of Immunology and Immunotherapy at the University of Birmingham and Deputy Head of the College of Medical and Dental Sciences. He is an international figure in translational human immunology and an NIHR Senior Investigator. He was previously Chair of the Infection and Immunity Board at the Medical Research Council and also served as Chair of the Clinical and Translational Research Committee at Cancer Research UK.

Professor Moss is currently leading the UK Coronavirus Immunology Consortium (UK-CIC), bringing together leading immunologists from 17 UK universities to understand the immune response to SARS-CoV-2. UK-CIC launched on 28 August 2020 with £6.5 million funding from UKRI and NIHR. It aims to determine the mechanisms of virus-specific immunity and how these relate to clinical outcome in different patient groups. The programme will also investigate the maintenance of long-term immunity and inform the development of vaccines and new therapies.

As well as publishing in leading journals, including Nature, Blood and the European Journal of Immunology, Professor Moss's research has featured in the Financial Times, BBC News and The Economist.


  • M.A. Medical Sciences (University of Cambridge)
  • B.M. B.S. (University of Oxford)
  • Member of Royal College of Physicians UK
  • Fellow of Royal College of Pathologists
  • Ph.D
  • Fellow of the Academy of Medical Sciences


Teaching Programmes

Teaching Activity

Professor Moss makes substantial contributions to teaching both within the University of Birmingham and beyond. He was previously Programme Director of the Intercalated Bachelor in Medical Sciences (Clinical Sciences) which offered medical students the opportunity to undertake an eight month research project during their undergraduate degree.


Research Themes

Professor Moss’s research programme is based around the immunology of cancer, transplantation and viral infection. His team has an internationally competitive position in cytomegalovirus infection; bone marrow transplantation and cancer immunology. 

Research Activity

Professor Moss’s research is focussed around the application of translational immunological research in the study of human disease. His current research group includes clinical and non-clinical research scientists working on a range of different projects:

The immune response to cancer

The group study the innate, adaptive and stromal response in several human cancers, including leukaemia and lymphoma, as well as pancreatic, ovarian and testicular cancer. Important technologies include flow sorting, CyTOF and single cell RNA-Seq.

Immune control of chronic human viral infection

With over 20 years of contribution within cytomegalovirus infection, the team continue to investigate the mechanisms and impact of chronic viral infection on human health.

Mechanisms of graft-versus-leukaemia following stem cell transplantation

Stem cell (bone marrow) transplantation can cure chemo-resistant cancer and the team are working with colleagues within the College of Medical and Dental Sciences to uncover the mechanisms of this effect.

The immunology of pregnancy

Pregnancy offers a major immunological challenge to the mother and several disorders of pregnancy may arise from a heightened fetal-specific ‘rejection’. In collaboration with Professor Mark Kilby, the team investigate the underlying mechanisms of immune homeostasis.

Additional research is undertaken with Professor Tatjana Stankovic on the genetics of Chronic Lymphocytic Leukaemia and with colleagues within University Hospitals Birmingham NHS Foundation Trust on research using clinical informatics.

Professor Moss's work is supported by four research programme grants and collaborations with industry. Several of his discoveries have been taken into clinical trials.

Professor Moss is a member of the UoA1 panel (Clinical Medicine) in REF 2021 and is on the Scientific Advisory Board for the MATWIN cancer open-innovation platform in France. 

Other activities

Clinical Activity/NHS Affiliation

Professor Moss is an Honorary Consultant at the University Hospitals Birmingham NHS Foundation Trust. His primary interests are in haemato-oncology and general haematology and he is the Clinical Service Lead for Chronic Lymphocytic Leukaemia. He became an NIHR Senior Investigator in 2018.

He is currently Chair of the UK Regenerative Medicine Platform, the Grants Advisory Panel at Prostate Cancer UK and the Epidemic Technical Advisory Panel at the Wellcome Trust. He is also Chair of the Innovate/MRC Biomedical Catalyst Major Awards Panel.

In addition he has previously held a number of important academic appointments:

  • Chair of the Infections and Immunity Board and member of Strategy Board at the Medical Research Council
  • Chair of the Cancer Research UK (CRUK) Clinical and Translational Research Committee (2008-2012)
  • Member of the Wellcome Trust Clinical Interview Committee
  • Deputy Chair of the MRC Infections and Immunity Board 2009-2013
  • Output assessor for Clinical Medicine Panel of Research Excellence Framework 2014 (REF2014)


Recent publications


Parry, H, McIlroy, G, Bruton, R, Ali, M, Stephens, C, Damery, S, Otter, A, McSkeane, T, Rolfe, H, Faustini, S, Wall, N, Hillmen, P, Pratt, G, Paneesha, S, Zuo, J, Richter, A & Moss, P 2021, 'Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia', Blood Cancer Journal, vol. 11, no. 7, 136.

Wood, H, Acharjee, A, Pearce, H, Quraishi, MN, Powell, R, Rossiter, A, Beggs, A, Ewer, A, Moss, P & Toldi, G 2021, 'Breastfeeding promotes early neonatal regulatory T-cell expansion and immune tolerance of non-inherited maternal antigens', Allergy.

Wall, N, Godlee, A, Geh, D, Jones, C, Faustini, S, Harvey, R, Penn, R, Chanouzas, D, Nightingale, P, O'Shea, M, Richter, A, Moss, P, Cunningham, A & Harper, L 2021, 'Latent cytomegalovirus infection and previous capsular polysaccharide vaccination predict poor vaccine responses in older adults, independent of chronic kidney disease', Clinical Infectious Diseases, vol. 2021, no. 00, ciab078, pp. 1-13.

Parry, HM, Dowell, AC, Zuo, J, Verma, K, Kinsella, FAM, Begum, J, Croft, W, Sharma-Oates, A, Pratt, G & Moss, P 2021, 'PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity', PLoS pathogens, vol. 17, no. 3, e1009349.

Zuo, J, Dowell, AC, Pearce, H, Verma, K, Long, HM, Begum, J, Aiano, F, Amin-Chowdhury, Z, Hallis, B, Stapley, L, Borrow, R, Linley, E, Ahmad, S, Parker, B, Horsley, A, Amirthalingam, G, Brown, K, Ramsay, ME, Ladhani, S & Moss, P 2021, 'Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection', Nature Immunology, vol. 22, no. 5, pp. 620-626.

Sethi, S, Kumar, A, Mandal, A, Shaikh, M, Hall, CA, Kirk, JMW, Moss, P, Brookes, MJ & Basu, S 2021, 'The UPTAKE study: implications for the future of COVID-19 vaccination trial recruitment in UK and beyond', Trials, vol. 22, no. 1, 296.

Sethi, S, Kumar, A, Mandal, A, Shaikh, M, Hall, CA, Kirk, J, Moss, P, Brookes, MJ & Basu, S 2021, 'The UPTAKE study: a cross-sectional survey examining the insights and beliefs of the UK population on COVID-19 vaccine uptake and hesitancy', British Medical Journal, vol. 11, no. 6, e048856, pp. 1-11.

Moss, P 2020, '"The ancient and the new": is there an interaction between cytomegalovirus and SARS-CoV-2 infection?', Immunity & Ageing, vol. 17, 14.

Wilkie, M, Satti, I, Minhinnick, A, Harris, S, Riste, M, Ramon, RL, Sheehan, S, Thomas, Z-RM, Wright, D, Stockdale, L, Hamidi, A, O'Shea, MK, Dwivedi, K, Behrens, HM, Davenne, T, Morton, J, Vermaak, S, Lawrie, A, Moss, P & McShane, H 2020, 'A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults', Vaccine, vol. 38, no. 4, pp. 779-789.

Frumento, G, Verma, K, Croft, W, White, A, Zuo, J, Nagy, Z, Kissane, S, Anderson, G, Moss, P & Chen, FE 2020, 'Homeostatic Cytokines Drive Epigenetic Reprogramming of Activated T Cells into a "Naive-Memory" Phenotype', iScience, vol. 23, no. 4, 100989.

Kwok, MCK, Oldreive, C, Rawstron, AC, Goel, A, Papatzikas, G, Jones, R, Drennan, S, Agathanggelou, A, Sharma-Oates, A, Evans, P, Smith, E, Dalal, S, Mao, J, Hollows, R, Gordon, N, Hamada, M, Davies, N, Parry, H, Beggs, A, Munir, T, Moreton, P, Paneesha, S, Pratt, G, Taylor, M, Forconi, F, Baird, D, Cazier, J-B, Moss, P, Hillmen, P & Stankovic, T 2020, 'Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL: natural history and mechanism of spontaneous CLL regression', Blood, vol. 135, no. 6, pp. 411-428.

Marcon, F, Zuo, J, Pearce, H, Nicol, S, Farhat, M, Davies, S, Middleton, G, Brown, R, Roberts, KJ & Moss, P 2020, 'NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype', OncoImmunology, vol. 9, no. 1, 1845424.

Karangizi, AHK, Chanouzas, D, Fenton, A, Moss, P, Cockwell, P, Ferro, CJ & Harper, L 2020, 'Response to: Cytomegalovirus seropositivity is independently associated with cardiovascular disease in non-dialysis dependent chronic kidney disease', QJM: An International Journal of Medicine, vol. 113, no. 9, pp. 702-703.


Banham, G, Godlee, A, Faustini, S, Cunningham, A, Richter, A, Harper, L, Backhouse, C, Casey, A, Dunbar, L, Emmanuel, B, Fahy, M, Moss, P, Nightingale, P, Ratcliffe, L & Stringer, S 2021, 'Hemodialysis patients make long-lived antibodies against SARSCOV-2 that may be associated with reduced reinfection', Journal of the American Society of Nephrology, vol. 32, no. 9, pp. 2140-2142.

Review article

Moss, P 2019, ''From immunosenescence to immune modulation': a re-appraisal of the role of cytomegalovirus as major regulator of human immune function', Medical Microbiology and Immunology, vol. 208, no. 3-4, pp. 271-280.

View all publications in research portal



Immune response to cancer; immunity to viruses and related health problems; evolution in clinical medicine.


Immune response; vaccinations.

Media experience

Multiple national and international media have quoted Professor Moss, including BBC News, The Economist, Reuters, The Guardian, and the Financial Times. In November 2020, he took part in a virtual press briefing held by the Science Media Centre to discuss a preprint relating to cellular immunity to SARS-CoV-2 in non-hospitalised individuals.

Alternative contact number available for this expert: contact the press office



Cancer, including immune response to cancer and evolution in clinical medicine.